NASDAQ:LMAT LeMaitre Vascular (LMAT) Stock Price, News & Analysis $88.06 -0.03 (-0.03%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$86.10▼$89.5050-Day Range$80.30▼$91.6752-Week Range$44.27▼$92.90Volume60,404 shsAverage Volume125,139 shsMarket Capitalization$1.98 billionP/E Ratio58.32Dividend Yield0.73%Price Target$94.40 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get LeMaitre Vascular alerts: Email Address LeMaitre Vascular MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside7.2% Upside$94.40 Price TargetShort InterestBearish5.37% of Float Sold ShortDividend StrengthStrongBased on Four FactorsSustainabilityN/ANews Sentiment1.42Based on 5 Articles This WeekInsider TradingSelling Shares$3.71 M Sold Last QuarterProj. Earnings Growth12.97%From $1.85 to $2.09 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.08 out of 5 starsMedical Sector319th out of 910 stocksSurgical & Medical Instruments Industry40th out of 95 stocks 1.5 Analyst's Opinion Consensus RatingLeMaitre Vascular has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageLeMaitre Vascular has only been the subject of 3 research reports in the past 90 days.Read more about LeMaitre Vascular's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.37% of the float of LeMaitre Vascular has been sold short.Short Interest Ratio / Days to CoverLeMaitre Vascular has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in LeMaitre Vascular has recently increased by 30.84%, indicating that investor sentiment is decreasing significantly. Previous Next 3.3 Dividend Strength Dividend YieldLeMaitre Vascular has a dividend yield of 0.72%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthLeMaitre Vascular has been increasing its dividend for 13 years.Dividend CoverageThe dividend payout ratio of LeMaitre Vascular is 42.38%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, LeMaitre Vascular will have a dividend payout ratio of 30.62% next year. This indicates that LeMaitre Vascular will be able to sustain or increase its dividend.Read more about LeMaitre Vascular's dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LMAT. Previous Next 4.1 News and Social Media Coverage News SentimentLeMaitre Vascular has a news sentiment score of 1.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for LeMaitre Vascular this week, compared to 3 articles on an average week.Search Interest1 people have searched for LMAT on MarketBeat in the last 30 days. MarketBeat Follows3 people have added LeMaitre Vascular to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, LeMaitre Vascular insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,714,994.00 in company stock.Percentage Held by Insiders10.79% of the stock of LeMaitre Vascular is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.64% of the stock of LeMaitre Vascular is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LeMaitre Vascular's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for LeMaitre Vascular are expected to grow by 12.97% in the coming year, from $1.85 to $2.09 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of LeMaitre Vascular is 58.32, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.25.Price to Earnings Ratio vs. SectorThe P/E ratio of LeMaitre Vascular is 58.32, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.15.Price to Earnings Growth RatioLeMaitre Vascular has a PEG Ratio of 2.38. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioLeMaitre Vascular has a P/B Ratio of 6.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about LeMaitre Vascular's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade About LeMaitre Vascular Stock (NASDAQ:LMAT)LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.Read More LMAT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LMAT Stock News HeadlinesAugust 17, 2024 | insidertrades.comDavid B. Roberts Sells 3,063 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) StockAugust 8, 2024 | insidertrades.comInsider Selling: LeMaitre Vascular, Inc. (NASDAQ:LMAT) Insider Sells 182 Shares of StockSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… August 31, 2024 | finance.yahoo.comLeMaitre Vascular (NASDAQ:LMAT) shareholders have earned a 25% CAGR over the last five yearsAugust 29, 2024 | americanbankingnews.comLeMaitre Vascular (NASDAQ:LMAT) Rating Lowered to Hold at StockNews.comAugust 27, 2024 | globenewswire.comLeMaitre to Participate at Upcoming Investor Conferences in SeptemberAugust 27, 2024 | markets.businessinsider.comLemaitre Vascular (LMAT) Gets a Buy from Lake StreetAugust 20, 2024 | markets.businessinsider.comLemaitre Vascular’s Strong Financial Performance and Growth Potential Warrant a Buy RatingSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… August 17, 2024 | msn.comIndonesia leader touts economic success in final state addressAugust 17, 2024 | finance.yahoo.comLeMaitre Vascular's (NASDAQ:LMAT) Returns Have Hit A WallAugust 16, 2024 | msn.comRobust Quarterly Result Lifted LeMaitre Vascular (LMAT) in Q2August 6, 2024 | ca.finance.yahoo.comLMAT Aug 2024 80.000 callAugust 3, 2024 | markets.businessinsider.comLemaitre Vascular’s Strong Performance and Promising Outlook Underpin Buy RatingAugust 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Lemaitre Vascular Amid Strong Fiscal Performance and Growth ProspectsAugust 2, 2024 | seekingalpha.comLeMaitre Vascular, Inc. (LMAT) Q2 2024 Earnings Call TranscriptAugust 1, 2024 | globenewswire.comLeMaitre Q2 2024 Financial ResultsAugust 1, 2024 | markets.businessinsider.comHere's what Wall Street expects from LeMaitre Vascular's earningsSee More Headlines Receive LMAT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LeMaitre Vascular and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Ex-Dividend for 8/29 Dividend8/15/2024Dividend Payable8/29/2024Today9/07/2024Next Earnings (Estimated)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:LMAT CUSIPN/A CIK1158895 Webwww.lemaitre.com Phone(781) 221-2266Fax781-425-5049Employees614Year Founded1983Price Target and Rating Average Stock Price Target$94.40 High Stock Price Target$105.00 Low Stock Price Target$75.00 Potential Upside/Downside+7.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$1.51 Trailing P/E Ratio58.32 Forward P/E Ratio47.60 P/E Growth2.38Net Income$30.10 million Net Margins18.33% Pretax Margin24.05% Return on Equity12.41% Return on Assets10.78% Debt Debt-to-Equity RatioN/A Current Ratio8.36 Quick Ratio5.86 Sales & Book Value Annual Sales$205.62 million Price / Sales9.61 Cash Flow$1.74 per share Price / Cash Flow50.57 Book Value$14.22 per share Price / Book6.19Miscellaneous Outstanding Shares22,446,000Free Float20,024,000Market Cap$1.98 billion OptionableOptionable Beta0.88 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. George W. LeMaitre (Age 59)Chairman & CEO Comp: $1.12MMr. David B. Roberts (Age 60)President & Director Comp: $634.85kMr. Joseph P. Pellegrino Jr. (Age 59)CFO, Secretary & Director Comp: $566.19kMr. Trent G. Kamke (Age 53)Senior Vice President of Operations Comp: $445.38kDr. George D. LeMaitre (Age 90)Founder and Chairman of Scientific Advisory Board Comp: $118.48kMr. David C. Hissong (Age 54)VP & General Counsel Ms. Kimberly L. Cieslak (Age 51)Vice President of Marketing Mr. Daniel J. Mumford (Age 42)Senior Director of Human Resources Mr. Maik D. Helmers (Age 50)Senior Vice President of Sales Central Europe Mr. Ryan H. Connelly (Age 47)Senior Vice President of Advanced Manufacturing Engineering More ExecutivesKey CompetitorsCardiovascular SystemsNASDAQ:CSIICryoLifeNYSE:CRYVapothermNYSE:VAPOGlaukosNYSE:GKOSStevanato GroupNYSE:STVNView All CompetitorsInsiders & InstitutionsTruist Financial CorpBought 3,381 shares on 8/21/2024Ownership: 0.031%Driehaus Capital Management LLCBought 90,573 shares on 8/16/2024Ownership: 1.177%Algert Global LLCSold 7,189 shares on 8/16/2024Ownership: 0.158%The Manufacturers Life Insurance Company Bought 583 shares on 8/15/2024Ownership: 0.047%Susquehanna Fundamental Investments LLCSold 1,457 shares on 8/15/2024Ownership: 0.017%View All Insider TransactionsView All Institutional Transactions LMAT Stock Analysis - Frequently Asked Questions How have LMAT shares performed this year? LeMaitre Vascular's stock was trading at $56.76 at the start of the year. Since then, LMAT shares have increased by 55.1% and is now trading at $88.06. View the best growth stocks for 2024 here. How were LeMaitre Vascular's earnings last quarter? LeMaitre Vascular, Inc. (NASDAQ:LMAT) released its quarterly earnings results on Thursday, August, 1st. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. The company's revenue for the quarter was up 11.4% on a year-over-year basis. What is George W. LeMaitre's approval rating as LeMaitre Vascular's CEO? 13 employees have rated LeMaitre Vascular Chief Executive Officer George W. LeMaitre on Glassdoor.com. George W. LeMaitre has an approval rating of 33% among the company's employees. This puts George W. LeMaitre in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. Does LeMaitre Vascular have any subsidiaries? LeMaitre Vascular subsidiaries include these companies: Artegraft, CardioCel, Tru-Incise (Eze-Sit) US, VascuCel, LeMaitre Cardial SAS, Syntel and Python, ProCol, and others. Who are LeMaitre Vascular's major shareholders? Top institutional investors of LeMaitre Vascular include Conestoga Capital Advisors LLC (8.65%), Dimensional Fund Advisors LP (2.86%), Driehaus Capital Management LLC (1.18%) and Rice Hall James & Associates LLC (1.01%). Insiders that own company stock include George W Lemaitre, David B Roberts, Joseph P Pellegrino Jr, Trent G Kamke, Bridget A Ross and John A Roush. View institutional ownership trends. How do I buy shares of LeMaitre Vascular? Shares of LMAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of LeMaitre Vascular own? Based on aggregate information from My MarketBeat watchlists, some other companies that LeMaitre Vascular investors own include AbbVie (ABBV), Sociedad Química y Minera de Chile (SQM), Gilead Sciences (GILD), Aurora Cannabis (ACBFF) and NVIDIA (NVDA). This page (NASDAQ:LMAT) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LeMaitre Vascular, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LeMaitre Vascular With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LMAT Stock Alerts